The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype

British Journal of Clinical Pharmacology

Volumn 42, Issue 4, 1996, Pages 471-474

  Wan, Jie ^a   Xia, Hui ^a   He, Nan ^a   Lu, Yi Qing ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

alcohol; Chinese; desmethyldiazepam; diazepam metabolism; mephenytoin oxidation

Indexed keywords

DIAZEPAM; DRUG METABOLITE; MEPHENYTOIN; NORDAZEPAM;

ADULT; ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; ARTICLE; CHINESE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OXIDATION; PHENOTYPE; PRIORITY JOURNAL;

EID: 0029842851     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00010.x     Document Type: Article

References (14)

1. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207.
2. de Morais SMF, Goldstein JA, Xie HG, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58: 404-411.
3. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S) mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-1752.
4. Wrighton SA, Stevens JC, Becker BW, Vanden Branden M. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993; 306: 240-245.
5. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 1994; 269: 15419-15422.
6. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598.
7. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe EJ, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1989; 45: 348-355.
8. Zhang Y, Reviriego J, Lou YQ, Sjöqvist F, Bertilsson L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: Interethnic differences in comparison with white subjects. Clin Pharmacol Ther 1990; 48: 496-502.
9. Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992; 52: 160-169.
10. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA, Wilkinson GR. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr 1984; 307: 121-127.
11. Klockowski PM, Levy G. Simultaneous determination of diazepam and its active metabolites in rat serum, brain and cerebrospinal fluid by high performance liquid chromatography. J Chromatogr 1987; 422: 334-339.
12. Cotler S, Puglisi CV, Gustafson JH. Determination of diazepam and its major metabolites in man and in the cat by high-performance liquid chromatography. J Chromatogr 1981; 222: 95-106.
13. m diazepam N-demethylase in livers of poor metabolisers for S-mephenytoin 4′-hydroxylation. Pharmacogenetics 1994; 4: 323-331.
14. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther 1993; 53: 608-610.